Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157

Current Pharmaceutical Design

Volumn 19, Issue 1, 2013, Pages 76-83

  Sikiric, Predrag ^a   Seiwerth, Sven ^a   Rucman, Rudolf ^a   Turkovic, Branko ^a   Rokotov, Dinko Stancic ^a   Brcic, Luka ^a   Sever, Marko ^a   Klicek, Robert ^a   Radic, Bozo ^a   Drmic, Domagoj ^a   Ilic, Spomenko ^a   Kolenc, Danijela ^a   Aralica, Gorana ^a   Safic, Hana ^a   Suran, Jelena ^a   Rak, Davor ^a   Dzidic, Senka ^a   Vrcic, Hrvoje ^a   Sebecic, Bozidar ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Antidote against NSAIDs; Aspirin prolonged bleeding; Counteraction; NSAIDs brain lesions; NSAIDs gastrointestinal tract lesions; NSAIDs liver lesions; Stable gastric pentadecapeptide BPC 157; Thrombocytopenia

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACETYLSALICYLIC ACID; ALLOXAN; ANTICOAGULANT AGENT; ANTIDOTE; ANTITHROMBOCYTIC AGENT; ANTIULCER AGENT; ARGININE; CAPSAICIN; CORTICOSTEROID; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; EPIRIZOLE; GASTRIC PENTADECAPEPTIDE; GLYCYLGLUTAMYLPROLYLPROLYLPROLYLGLYCYLLYSYLPROLYLALANYLASPARTYLASPARTYLALANYLGLYCYLLEUCYLVALINE; HALOPERIDOL; IBUPROFEN; INDOMETACIN; N ACETYL 1,4 BENZOQUINONE IMINE; N(G) NITROARGININE METHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENTETRAZOLE; PHENYLBUTAZONE; PIROXICAM; QUINOLONE DERIVATIVE; RESERPINE; SULINDAC; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT ARTHRITIS; ANTIULCER ACTIVITY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BLOOD VESSEL FUNCTION; BRAIN DAMAGE; BRAIN INJURY; CELL PROTECTION; DIGESTIVE SYSTEM INJURY; DRUG MECHANISM; DRUG SAFETY; DRUG STABILITY; DUODENUM INJURY; ENTERITIS; HUMAN; HYPERTHERMIA; HYPOTHERMIA; INTESTINE INJURY; LIVER INJURY; LIVER TOXICITY; NONHUMAN; PAIN; PRIORITY JOURNAL; STOMACH INJURY; THROMBOCYTOPENIA; THROMBUS; WOUND HEALING;

EID: 84873980680     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128130111     Document Type: Article

References (112)

1. Sikiri P, Petek M, Rucman R, Seiwerth S, Grabarevi Z, Rotkvi I, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris 1993; 87: 313-27.
2. Sikiric P, Seiwerth S, Brcic L, Sever M, Klicek R, Radic B, et al. Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Possible significance and implications for novel mediator. Curr Pharm Des 2010; 16(10): 1224-34.
3. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des 2011; 17: 1612-32.
4. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157. Curr Med Chem 2012; 19: 126-32.
5. Ilic S, Drmic D, Zarkovic K, Kolenc D, Coric M, Brcic L, et al. High hepatotoxic dose of paracetamol produces generalized convulsions and brain damage in rats. A counteraction with the stable gastric pentadecapeptide BPC 157 (PL 14736). J Physiol Pharmacol 2010; 61: 241-50.
6. Ilic S, Drmic D, Franjic S, Kolenc D, Coric M, Brcic L, et al. Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions. Life Sci 2011; 88: 535-42.
7. Ilic S, Drmic D, Zarkovic K, Kolenc D, Brcic L, Radic B, et al. Ibuprofen hepatic encephalopathy, hepatomegaly, gastric lesion and gastric pentadecapeptide BPC 157 in rats. Eur J Pharmacol 2011; 667: 322-9.
8. Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Jagic V, et al. Pentadecapeptide BPC 157 positively affects both nonsteroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats. J Physiol Paris 1997; 91: 113-22.
9. Boban Blagaic A, Blagaic V, Mirt M, Jelovac N, Dodig G, Rucman R, et al. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. Eur J Pharmacol 2005; 512: 173-9.
10. Hrelec M, Klicek R, Brcic L, Brcic I, Cvjetko I, Seiwerth S, et al. Abdominal aorta anastomosis in rats and stable gastric pentadecapeptide BPC 157, prophylaxis and therapy. J Physiol Pharmacol 2009; 60(Suppl 7): 161-5.
11. Stupnisek M, Franjic S, Drmic D, Hrelec M, Kolenc D, Radic B, et al. Pentadecapeptide BPC 157 reduces bleeding time and thrombocytopenia after amputation in rats treated with heparin, warfarin or aspirin. Thromb Res 2011; Aug 12. [Epub ahead of print]
12. Sikiric P, Seiwerth S, Mise S, Staresinic M, Bedekovic V, Zarkovic N, et al. Corticosteroid-impairment of healing and gastric pentadecapeptide BPC-157 creams in burned mice. Burns 2003; 29: 323-34.
13. Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol 2009; 60(Suppl 7): 191-6.
14. Robert A. Cytoprotection by prostaglandins. Gastroenterology 1979; 77: 761-7.
15. Collier HO. The story of aspirin. In: Parnham MJ, Bruinvels J, Eds. Discovery in Pharmacology, Volume 2: Haemodynamics, Hormones & Inflammation. Amsterdam New York Oxford: Elsevier Sccience Publishers B.V. 1984; pp. 555-593.
16. Collier HO, James GW, Piper PJ. Antagonism by fenamates and like-acting drugs of bronchoconstriction induced by bradykinin or antigen in the guinea-pig. Br J Pharmacol 1968; 34: 76-87.
17. Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 1972; 240: 410-1.
18. Collier HO, Roy AC. Hypothesis: Inhibition of E prostaglandinsensitive adenyl cyclase as the mechanism of morphine analgesia. Prostaglandins 1974; 7: 361-76.
19. Manov I, Motanis H, Frumin I, Iancu TC. Patotoxicity of antiinflammatory and analgesic drugs: ultrastructural aspects. Acta Pharmacol Sin 2006; 27: 259-72.
20. Shen TY. The proliferation of non-steroidal anti-inflammatory drugs (NSAIDS). In: Parnham MJ, Bruinvels J, Eds. Discovery in Pharmacology, Volume 2: Haemodynamics, Hormones & Inflammation. Amsterdam New York Oxford: Elsevier Sccience Publishers B.V. 1984; pp. 523-553.
21. Robert A, Lancaster C, Olafsson AS et al: Gastric adaptation to the ulcerogenic effect of aspirin. Exp Clin Gastroenterol, 1991; 1: 73-81. nema u PUB Medu
22. Sikiric P, Seiwerth S, Grabarevic Z, Petek M, Rucman R, Turkovic B, et al. The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides. Life Sci 1994; 54: PL63-8.
23. Sikiri P, Seiwerth S, Deskovi S, Grabarevi Z, Marovi A, Rucman R, et al. New model of cytoprotection/adaptive cytoprotection in rats: endogenous small irritants, antiulcer agents and indomethacin. Eur J Pharmacol 1999; 364: 23-31.
24. Sikiri P, Seiwerth S, Grabarevi Z, Rucman R, Petek M, Jagi V, et al. Beneficial effect of a novel pentadecapeptide BPC 157 on gastric lesions induced by restraint stress, ethanol, indomethacin, and capsaicin neurotoxicity. Dig Dis Sci 1996; 41: 1604-14.
25. Skorjanec S, Dolovski Z, Kocman I, Brcic L, Blagaic Boban A, Batelja L, et al. Therapy for unhealed gastrocutaneous fistulas in rats as a model for analogous healing of persistent skin wounds and persistent gastric ulcers: stable gastric pentadecapeptide BPC 157, atropine, ranitidine, and omeprazole. Dig Dis Sci 2009; 54: 46-56.
26. Xue XC, Wu YJ, Gao MT, Li WG, Zhao N, Wang ZL, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol 2004; 10: 1032-6.
27. Bilic I, Zoricic I, Anic T, Separovic J, Stancic-Rokotov D, Mikus D, et al. Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice. Life Sci 2001; 68: 1905-12.
28. Jelovac N, Sikiric P, Rucman R, Petek M, Marovic A, Perovic D, et al. Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats. Eur J Pharmacol 1999; 379: 19-31.
29. Sikiri P, Mazul B, Seiwerth S, Grabarevi Z, Rucman R, Petek M, et al. Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress. Dig Dis Sci 1997; 42: 661-71.
30. Sikiric P, Separovic J, Buljat G, Anic T, Stancic-Rokotov D, Mikus D, et al. Gastric mucosal lesions induced by complete dopamine system failure in rats. The effects of dopamine agents, ranitidine, atropine, omeprazole and pentadecapeptide BPC 157. J Physiol Paris 2000; 94: 105-10.
31. Ilic S, Brcic I, Mester M, Filipovic M, Sever M, Klicek R, et al. Over-dose insulin and stable gastric pentadecapeptide BPC 157. Attenuated gastric ulcers, seizures, brain lesions, hepatomegaly, fatty liver, breakdown of liver glycogen, profound hypoglycemia and calcification in rats. J Physiol Pharmacol 2009; 60 Suppl 7: 107-14.
32. Petek M, Sikiric P, Anic T, Buljat G, Separovic J, Stancic-Rokotov D, et al. Pentadecapeptide BPC 157 attenuates gastric lesions induced by alloxan in rats and mice. J Physiol Paris 1999; 93: 501-4.
33. Sikiri P, Seiwerth S, Grabarevi Z, Rucman R, Petek M, Jagi V, et al. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. Eur J Pharmacol 1997; 332: 23-33.
34. Stancic-Rokotov D, Sikiric P, Seiwerth S, Slobodnjak Z, Aralica J, Aralica G, et al. Ethanol gastric lesion aggravated by lung injury in rat. Therapy effect of antiulcer agents. J Physiol Paris 2001; 95: 289-93.
35. Prkacin I, Aralica G, Perovic D, Separovic J, Gjurasin M, Lovric-Bencic M, et al. Chronic cytoprotection pentadecapeptide BPC 157, ranitidine and propranolol prevent, attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats. J Physiol Paris 2001; 95: 295-301.
36. Bódis B, Karádi O, Nagy L, Dohoczky C, Kolega M, Mózsik G. Direct cellular effects of some mediators, hormones and growth factor-like agents on denervated (isolated) rat gastric mucosal cells. J Physiol Paris 1997; 91: 183-7.
37. Bódis B, Karádi O, Németh P, Dohoczky C, Kolega M, Mózsik G. Evidence for direct cellular protective effect of PL-10 substances (synthesized parts of body protection compound, BPC) and their specificity to gastric mucosal cells. Life Sci 1997; 61: PL 243-8.
38. Tohyama Y, Sikiri P, Diksic M. Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alphamethyl-L-tryptophan autoradiographic measurements. Life Sci 2004; 76: 345-57.
39. Sikiric P, Marovic A, Matoz W, Anic T, Buljat G, Mikus D, et al. A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine. J Physiol Paris 1999; 93: 505-12.
40. Seveljevi-Jaran D, Cuzi S, Dominis-Kramari M, Glojnari I, Iveti V, Radosevi S, et al. Accelerated healing of excisional skin wounds by PL 14736 in alloxan-hyperglycemic rats. Skin Pharmacol Physiol 2006; 19: 266-74.
41. Kalogjera L, Ries M, Baudoin T, Ferencic Z, Trotic R, Pegan B. Dose-dependent protective effect of BPC 157 on capsaicin-induced rhinitis in rats. Eur Arch Otorhinolaryngol 1997; 254(Suppl 1): S9-11.
42. Seiwerth S, Sikiric P, Grabarevic Z, Zoricic I, Hanzevacki M, Ljubanovic D, et al. BPC 157's effect on healing. J Physiol Paris 1997; 91: 173-8.
43. Sikiric P, Separovic J, Anic T, Buljat G, Mikus D, Seiwerth S, et al. The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation. J Physiol Paris 1999; 93: 479-85.
44. Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol 2009; 60(Suppl 7): 191-6.
45. Mozsik G, Sikiric P, Seiwerth S. Pentadecapeptide BPC 157 (PLD116, PL14736, Pliva) infl uences ATP energy system and antagonizes 0.6 M HCl-and 96 % ethanol-gastric lesion in rat. Digestion 2006; 73(Suppl 2): 41.
46. Ueshima K, Takeuchi K, Ohuchi T, Okabe S. Acid secretory and duodenal ulcerogenic responses induced by mepirizole in anesthetized rats. Relation to body temperature. Dig Dis Sci 1994; 39: 1625-32.
47. Dobric I, Drvis P, Petrovic I, Shejbal D, Brcic L, Blagaic AB, et al. Prolonged esophagitis after primary dysfunction of the pyloric sphincter in the rat and therapeutic potential of the gastric pentadecapeptide BPC 157. J Pharmacol Sci 2007; 104: 7-18.
48. Petrovic I, Dobric I, Drvis P, Shejbal D, Brcic L, Blagaic AB, et al. An experimental model of prolonged esophagitis with sphincter failure in the rat and the therapeutic potential of gastric pentadecapeptide BPC 157. J Pharmacol Sci 2006; 102: 269-77.
49. Petrovic I, Dobric I, Drmic D, Sever M, Klicek R, Radic B, et al. BPC 157 therapy to detriment sphincters failure-esophagitispancreatitis in rat and acute pancreatitis patients low sphincters pressure. J Physiol Pharmacol 2011; 62: 527-34.
50. Franjic S, Drmic D, Bauk L, Stupnisek M, Becejac T, Radi B, et al. Pentadecapeptide BPC 157 counteracts failure of lower esophageal and pyloric sphincter induced by NSAIDs in rats. Gastroenterology 2011; 140(5): S-232.
51. Szabo S, Neumeyer JL. Dopamine agonists and antagonists in duodenal ulcer disease. In: Kaiser C, Kebabian W, Eds. Symposium Series. Washington: ACS American Chemical Society Publications 1983; 224: 175-96.
52. Sikiric P, Seiwerth S, Grabarevic Z, Balen I, Aralica G, Gjurasin M, et al. Cysteamine-colon and cysteamine-duodenum lesions in rats. Attenuation by gastric pentadecapeptide BPC 157, cimetidine, ranitidine, atropine, omeprazole, sulphasalazine and methylprednisolone. J Physiol Paris 2001; 95: 261-70.
53. Bedekovic V, Mise S, Anic T, Staresinic M, Gjurasin M, Kopljar M, et al. Different effect of antiulcer agents on rat cysteamineinduced duodenal ulcer after sialoadenectomy, but not gastrectomy. Eur J Pharmacol 2003; 477: 73-80.
54. Skorjanec S, Dolovski Z, Sever M, Klicek R, Drmic D, Radic B, et al. Stable gastric pentadecapeptide BPC 157 may heal duodenocutaneous fistulas in rats. Gastroenterology 2011; 140(5): S-656.
55. Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 2004; 63: 759-66.
56. Sikiric P, Seiwerth S, Aralica G, Perovic D, Staresinic M, Anic T, et al. Therapy effect of antiulcer agents on new chronic cysteamine colon lesion in rat. J Physiol Paris 2001; 95: 283-8.
57. Veljaca M, Lesch CA, Pllana R, Sanchez B, Chan K, Guglietta A. BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. J Pharmacol Exp Ther 1995; 272: 417-22.
58. Vuksic T, Zoricic I, Brcic L, Sever M, Klicek R, Radic B, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. Surg Today 2007; 37: 768-77.
59. Klicek R, Sever M, Radic B, Drmic D, Kocman I, Zoricic I, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. J Pharmacol Sci 2008; 108: 7-17.
60. Sever M, Klicek R, Radic B, Brcic L, Zoricic I, Drmic D, et al. Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats. Dig Dis Sci 2009; 54: 2070-83.
61. Lojo N, Rasic Z, Baric M, Sever M, Romic Z, Seiwerth S, et al. The effect of pentadecapeptide BPC 157 and high dose diclofenac on induced short bowel syndrome. Gastroenterology 2011; 140(5): S-505.
62. Deng X, Liguori MJ, Sparkenbaugh EM, Waring JF, Blomme EA, Ganey PE, et al. Gene expression profiles in livers from diclofenactreated rats reveal intestinal bacteria-dependent and-independent pathways associated with liver injury. J Pharmacol Exp Ther 2008; 327: 634-44.
63. Deng X, Szabo S, Khomenko T, Jadus MR, Yoshida M, Chen L. Detection of duodenal ulcer-associated genes in rats. Dig Dis Sci 2008; 53: 375-84.
64. Fukuda M, Kitaichi K, Abe F, Fujimoto Y, Takagi K, Takagi K, et al. Altered brain penetration of diclofenac and mefenamic acid, but not acetaminophen, in Shiga-like toxin II-treated mice. J Pharmacol Sci 2005; 97: 525-32.
65. Situm A, Klicek R, Barbaric M, Drmic D, Boban Blagaic A, Seiwerth S, et al. The Healing of Colocutaneous Fistulas and Bile Duct Ligation. The Role of Pentadecapeptide BPC 157. Gastroenterology 2011; 140(5): S-458.
66. Zoricic I, Sikiric P, Seiwerth S. Pentadecapeptide BPC 157 beneficially influences the healing of colon-colon anastomoses in rats. In: Mozsik G, Nagy L, Par A, Rainsford KD, Eds. Cell injury and protection in the gastrointestinal trace. From basic sciences to clinical perspectives 1996. Dordrecht Boston London: Kluwer AcademicPublishers; 1997; pp. 249-58.
67. Nelson SD. Mechanisms of the formation and disposition of reactive metabolites that can cause acute liver injury. Drug Metab Rev 1995; 27: 147-77.
68. Pumford NR, Halmes NC, Hinson JA. Covalent binding of xenobiotics to specific proteins in the liver. Drug Metab Rev 1997; 29: 39-57.
69. Muldrew KL, James LP, Coop L, McCullough SS, Hendrickson HP, Hinson JA, et al. Determination of acetaminophen-protein adducts in mouse liver and serum and human serum after hepatotoxic doses of acetaminophen using high-performance liquid chromatography with electrochemical detection. Drug Metab Dispos 2002; 30: 446-51.
70. Lewis JHL. Drug-induced liver disease. Gastroenterol Clin North Am 2000; 84: 1275-1311.
71. Schoonen WG, Kloks CP, Ploemen JP, Smit MJ, Zandberg P, Horbach GJ, et al. Uniform procedure of (1)H NMR analysis of rat urine and toxicometabonomics Part II: comparison of NMR profiles for classification of hepatotoxicity. Toxicol Sci 2007; 98: 286-97.
72. Siegers CP, Heger B, Baretton G, Younes M. Inhibition of halothane-induced lipid peroxidation by misoprostol without hepatoprotection. Toxicology 1988; 53: 213-8.
73. Burkhart KK, Janco N, Kulig KW, Rumack BH. Cimetidine as adjunctive treatment for acetaminophen overdose. Hum Exp Toxicol 1995; 14: 299-304.
74. Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Rotkvic I, et al. Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin. Life Sci 1993; 53: PL291-6.
75. Prkacin I, Separovic J, Aralica G, Perovic D, Gjurasin M, Lovric-Bencic M, et al. Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine. J Physiol Paris 2001; 95: 315-24.
76. Jelovac N, Sikirí P, Rucman R, Petek M, Peroví D, Konjevoda P, et al. A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine. Biol Psychiatry 1998; 43: 511-9.
77. Sikiric P, Jelovac N, Jelovac-Gjeldum A, Dodig G, Staresinic M, Anic T, et al. Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances. Acta Pharmacol Sin 2002; 23(5): 412-22.
78. Boban Blagaic A, Turcic P, Blagaic V, Dubovecak M, Jelovac N, Zemba M, et al. Gastric pentadecapeptide BPC 157 counteracts morphine-induced analgesia in mice. J Physiol Pharmacol 2009; 60(Suppl 7): 177-81.
79. Blagaic AB, Blagaic V, Romic Z, Sikiric P. The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice. Eur J Pharmacol 2004; 499: 285-90.
80. Sikiric P, Jelovac N, Jelovac-Gjeldum A, Dodig G, Staresinic M, Anic T, et al. Anxiolytic effect of BPC-157, a gastric pentadecapeptide: shock probe/burying test and light/dark test. Acta Pharmacol Sin 2001; 22: 225-30.
81. Lozeva-Thomas V. Serotonin brain circuits with a focus on hepatic encephalopathy. Metab Brain Dis 2004; 19: 413-20.
82. Nencini C, Giorgi G, Micheli L. Protective effect of silymarin on oxidative stress in rat brain. Phytomedicine 2007; 14: 129-135.
83. Floyd RA. Antioxidant oxidative stress, and degenerativeneurological disorders. Proc Soc Exp Biol Med 1999; 222: 236-245.
84. Scorticati C, Prestifilippo JP, Eizayaga FX, Castro JL, Romay S, Fernández MA, et al. Hyperammonemia, brain edema and bloodbrain barrier alterations in prehepatic portal hypertensive rats and paracetamol intoxication. World J Gastroenterol 2004; 10: 1321-1324.
85. Steinhauer HB, Hertting G. Lowering of the convulsive threshold by non-steroidal anti-inflammatory drugs. Eur J Pharmacol 1981; 69: 199-203.
86. Hori S, Kizu J, Kawamura M. Effects of anti-inflammatory drugs on convulsant activity of quinolones: a comparative study of drug interaction between quinolones and anti-inflammatory drugs. J Infect Chemother 2003; 9: 314-320.
87. Fetveit A. Assessment of febrile seizures in children. Eur J Pediatr 2008; 167: 17-27.
88. Wallenstein MC. Differential effects of prostaglandin synthetase inhibitors on EEG in rat. Eur J Pharmacol 1985; 111: 201-209.
89. Bergman K, Muller L, Weberg Teigen S. The genotoxicityand carcinogenicity of paracetamol: a regulatory (re)view. Mut Res 1996; 349: 263-288.
90. Bendele AM, Hulman JF, White S, Brodhecker C, Bendele RAHepatocellular proliferation in ibuprofen-treated mice. Toxicol Pathol 1993; 21: 15-20.
91. Vale JA, Meredith TJ. Acute poisoning due to non-steroidal antiinflammatory drugs. Clinical features and management. Med Toxicol 1986; 1: 12-31.
92. Fontana RJ. Acute liver failure including acetaminophen overdose. Med Clin North Am 2008; 92: 761-794.
93. Beck EA. The treatment of thrombosis. In: Parnham MJ, Bruinvels J, Eds. Discovery in Pharmacology, Volume 2: Haemodynamics, Hormones & Inflammation. Amsterdam New York Oxford: Elsevier Sccience Publishers B.V. 1984; pp. 127-140.
94. Bilic M, Bumber Z, Blagaic AB, Batelja L, Seiwerth S, Sikiric P. The stable gastric pentadecapeptide BPC 157, given locally, improves CO2 laser healing in mice. Burns 2005; 31: 310-5.
95. Mikus D, Sikiric P, Seiwerth S, Petricevic A, Aralica G, Druzijancic N, et al. Pentadecapeptide BPC 157 cream improves burnwound healing and attenuates burn-gastric lesions in mice. Burns 2001; 27: 817-27.
96. Lazí R, Gabrí N, Dekaris I, Bosnar D, Boban-Blagaí A, Sikirí P. Gastric pentadecapeptide BPC 157 promotes corneal epithelial defects healing in rats. Coll Antropol 2005; 29: 321-5.
97. Staresinic M, Petrovic I, Novinscak T, Jukic I, Pevec D, Suknaic S, et al. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. J Orthop Res 2006; 24: 1109-17.
98. Novinscak T, Brcic L, Staresinic M, Jukic I, Radic B, Pevec D, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today 2008; 38: 716-25.
99. Pevec D, Novinscak T, Brcic L, Sipos K, Jukic I, Staresinic M, et al. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit 2010; 16: BR81-88.
100. Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, Perovic D, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res 2003; 21: 976-83.
101. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res 2006; 24: 982-9.
102. Krivic A, Majerovic M, Jelic I, Seiwerth S, Sikiric P. Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone. Inflamm Res 2008; 57: 205-10.
103. Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res 2010; 28: 1155-61.
104. Tudor M, Jandric I, Marovic A, Gjurasin M, Perovic D, Radic B, et al. Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. Regul Pept 2010; 160: 26-32.
105. Gjurasin M, Miklic P, Zupancic B, Perovic D, Zarkovic K, Brcic L, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regul Pept 2010; 160: 33-41.
106. Sebecí B, Nikolí V, Sikirí P, Seiwerth S, Sosa T, Patrlj L, et al. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation. Bone 1999; 24: 195-202.
107. Keremi B, Lohinai Z, Komora P, Duhaj S, Borsi K, Jobbagy-Ovari G, et al. Antiinflammatory effect of BPC 157 on experimental periodontitis in rats. J Physiol Pharmacol 2009; 60(Suppl 7): 115-22.
108. Tkalcevic VI, Cuzic S, Brajsa K, Mildner B, Bokulic A, Situm K, et al. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Eur J Pharmacol 2007; 570: 212-21.
109. Silverman ES, Khachigian LM, Santiago FS, Williams AJ, Lindner V, Collins T. Vascular smooth muscle cells express the transcriptional corepressor NAB2 in response to injury. Am J Pathol 1999; 155: 1311-7.
110. Donohue Jr TM. Alcohol-induced steatosis in liver cells. World J Gastroenterol 2007; 13: 4974-8.
111. Pritchard MT, Roychowdhury S, McMullen MR, Guo L, Arteel GE, Nagy LE. Early growth response-1 contributes to galactosamine/lipopolysaccharideinduced acute liver injury in mice. Am J Physiol Gastrointest Liver Physiol 2007; 293: G1124-33.
112. Szabó IL, Pai R, Soreghan B, Jones MK, Baatar D, Kawanaka H. NSAIDs inhibit the activation of egr-1 gene in microvascular endothelial cells. A key to inhibition of angiogenesis? J Physiol Paris 2001; 95: 379-83.